Published Research
Can research, data, and technology aid the development of psychedelic medicine?
Carhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. "Can Pragmatic Research, Real-World Data, and Digital Technologies Aid the Development of Psychedelic Medicine?" Journal of Psychopharmacology, Jan 2022.
The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder
Agrawal M., Thambi P., Shnayder S. "The Safety and Efficacy Of Psilocybin Therapy in Patients with Cancer and Major Depressive Disorder" Journal of Clinical Oncology, June 2022.
Psilocybin-assisted therapy improves psychosocial well-being in cancer patients
Shnayder S., Amelia R., Sinai., Berger A., Agrawal M. “Psilocybin-assisted therapy improves psycho-social-well-being in cancer patients.” Journal of Affective Disorders, Dec 2022.
Psilocybin therapy for patients with cancer and major depression disorder
Select Agrawal M., Emanuel E., Richards B., et al. “Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder.” JAMA Oncology, April 2023.
Psilocybin‐assisted group therapy in patients diagnosed with cancer and depression
Agrawal M., Richards W., Beaussant Y., et al. “Psilocybin‐assisted group therapy in patients with cancer diagnosed with a major depressive disorder.” Cancer, July 2023.
Direct observation measure of therapeutic connection in psilocybin-assisted therapy
Gramling R., Bennett E., Curtis K., et al. “Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.” Journal of Palliative Medicine, August 2023.
Group psychedelic therapy: empirical estimates of cost-savings and improved access
Marseille E., Stauffer C., Agrawal M., et al. “Group psychedelic therapy: empirical estimates of cost-savings and improved access.” Front. Psychiatry, Dec. 2023.
Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD
Beaussant Y., Tarbi E., Nigam K., et al. “Acceptability of psilocybin-assisted group therapy in patients with cancer and MDD.” Cancer, Dec 2023.
The potential for psychedelics to treat Prolonged Grief Disorder
Ehrenkranz R., Agrawal M., Penberthy J., Yaden., D. "Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder." International Review of Psychiatry, May 2024.
Adverse events should not be surprising in psychedelic research
Ehrenkranz R., Agrawal M., Nayak S., Yaden., D. "Adverse Events Should Not Be Surprising in Psychedelic Research." Psychedelic Medicine, September 2024.
The epidemiology of psychedelic use among U. S. military veterans
Davis A., Bates M., Koffman R., et al. “The Epidemiology of Psychedelic Use Among United States Military Veterans.” Journal of Psychoactive Drugs, Sep 2024.
Long-term benefits of single-dose psilocybin in depressed cancer patients
Agrawal M., Emanuel E., Jenkins B., et al. "Long-term Benefits of Single-Dose Psilocybin in Depressed Cancer Patients." Cancer, June 2025.